Single-dose extended-release oral azithromycin vs. 3-day azithromycin for the treatment of group A β-haemolytic streptococcal pharyngitis/tonsillitis in adults and adolescents: A double-blind, double-dummy study

Clinical Microbiology and Infection

Volumn 15, Issue 12, 2009, Pages 1103-1110

  Jorgensen, D M ^a  

^a PFIZER INC   (United States)

Author keywords

Azithromycin; Extended release; Group A streptococcal infection; Pharyngitis; Tonsillitis

Indexed keywords

AZITHROMYCIN;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; GROUP A STREPTOCOCCAL INFECTION; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SINGLE DRUG DOSE; TONSILLITIS;

EID: 70649113651     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02718.x     Document Type: Article

References (30)

1. Gwaltney JM, Bisna AL, Mandell GL, Bennett JE, Dolin R. Pharyngitis. Principles and practice of infectious diseases 2000, 656-662. In, eds, 5th edn, Philadelphia, PA, Churchill Livingstone
2. Müller O. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections. J Antimicrob Chemother 1996, 37(suppl C):83-92.
3. Müller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1993, 31(suppl E):137-146.
4. O'Doherty B. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1996, 37(suppl C):71-81.
5. Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin Infect Dis 2005, 40:1748-1755.
6. Blasi F, Aliberti S, Tarsia P. Clinical applications of azithromycin microspheres in respiratory tract infections. Int J Nanomedicine 2007, 2:551-559.
7. Craig WA, Zinner SH, Young LS, Acar JF, Neu HC. Postantibiotic effects and the dosing of macrolides, azalides and streptogramins. Expanding indications of the new macrolides, azalides and streptogramins 1997, 22-38. In, eds, New York, Marcel Dekker
8. Girard D, Finegan SM, Dunne MW, Lame ME. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 2005, 56:365-371.
9. D'Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005, 49:4035-4041.
10. Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005, 128:2230-2237.
11. Zervos M, Breen JD, Jorgensen DM, Goodrich JM. Novel, single-dose microsphere formulation of azithromycin versus levofloxacin for the treatment of acute exacerbation of chronic bronchitis. Infect Dis Clin Pract 2005, 13:115-121.
12. Murray JJ, Emparanza P, Lesinskas E, Tawadrous M, Breen JD. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg 2005, 133:194-200.
13. Pichichero ME, Cohen R. Empiric antibiotic selection criteria for respiratory infections in pediatric practice. Pediatr Infect Dis J 1997, 16:680-695.
14. Bisno AL, Gerber MA, Gwaltney JM, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002, 35:113-125.
15. Kaplan EL, Johnson DR. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics 2001, 108:1180-1186.
16. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. Clin Infect Dis 2004, 38:1526-1534.
17. Brook I. A pooled comparison of cefdinir and penicillin in the treatment of group A beta-hemolytic streptococcal pharyngotonsillitis. Clin Ther 2005, 27:1266-1273.
18. Takker U, Dzyublyk O, Busman T, Notario G. Comparison of 5 days of extended-release clarithromycin versus 10 days of penicillin V for the treatment of streptococcal pharyngitis/tonsillitis: results of a multicenter, double-blind, randomized study in adolescent and adult patients. Curr Med Res Opin 2003, 19:421-429.
19. Portier H, Filipecki J, Weber P, Goldfarb G, Lethuaire D, Chauvin JP. Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multi-centre, open-label, randomized study. J Antimicrob Chemother 2002, 49:337-344.
20. Wong DM, Blumberg DA, Lowe LG. Guidelines for the use of antibiotics in acute upper respiratory tract infections. Am Fam Physician 2006, 74:956-966.
21. Kaplan E, Johnson D, Del Rosario M, Horn D. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J 1999, 18:1069-1072.
22. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002, 346:1200-1206.
23. Seppälä H, Klaukka T, Vuopio-Varkila J. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997, 337:441-446.
24. Gagliotti C, Nobilio L, Milandri M, Moro ML. Emilia-Romagna Antibiotic Resistance Study Group. Macrolide prescriptions and erythromycin resistance of Streptococcus pyogenes. Clin Infect Dis 2006, 42:1153-1156.
25. Bingen E, Bidet P, Mihaila-Amrouche L. Emergence of macrolide-resistant Streptococcus pyogenes strains in French children. Antimicrob Agents Chemother 2004, 48:3559-3562.
26. Cleary P, Kaplan E, Handley J, Schlievert P. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 1992, 339:518-521.
27. Urbánek K, Kolár M, Cekanová L. Utilization of macrolides and the development of Streptococcus pyogenes resistance to erythromycin. Pharm World Sci 2005, 27:104-107.
28. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002, 360:835-841. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group
29. Agarwal G, Awasthi S, Kabra SK. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ 2004, doi, DE. [Epub ahead of print]
30. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002, 49:897-903.